To Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
Researchers are conducting a study to test a new combination treatment for multiple myeloma, a type of blood cancer. This treatment involves a new drug called XMAB24306, given alongside an already approved medicine called daratumumab. The study is for adults in the UK whose multiple myeloma has either returned after previous treatment or isn't responding to their current medicines. The main goals are to find out if this new combination is safe for people to take and to understand how the body processes XMAB24306. This is an early-stage study, meaning it's one of the first times this new drug combination is being tested in humans.
At a glance
What is this study about?
This study is designed to explore a new way to treat multiple myeloma, which is a type of cancer that affects plasma cells in the bone marrow and can create abnormal proteins, leading to a variety of health problems. Sometimes, after initial treatments, multiple myeloma can come back (this is called 'relapsed') or unfortunately, the existing treatments stop working effectively (this is called 'refractory'). When this happens, doctors and patients look for new options.
That's where this study comes in. Researchers are testing a new medicine called XMAB24306 in combination with a medicine called daratumumab, which is already used to treat multiple myeloma. The study wants to understand how safe this new combination is when given to people, and also how the body processes the new drug XMAB24306. This includes looking at how it's absorbed, distributed, broken down, and removed from the body.
This kind of research is really important because it helps scientists learn more about new potential treatments. By carefully studying how a new drug works and if it's safe at an early stage, they can decide if it should be tested in larger groups of people. The ultimate goal is to find better and safer ways to help people living with multiple myeloma.
Key takeaways
- This study is for adults with multiple myeloma that has come back or is no longer responding to treatment.
- It's testing a new drug, XMAB24306, combined with an existing medicine, daratumumab.
- The main goals are to check for safety and how the body handles the new drug.
- This is an early-stage study, helping scientists learn more about new potential treatments.
- Participation involves regular clinic visits for treatment and monitoring your health.
Who may be eligible?
To join this study, you must be an adult aged 18 or over. Both men and women can participate. The study is specifically for people whose multiple myeloma has returned after previous treatments or is no longer responding well to their current treatment.
There might be other health requirements or previous treatment details that determine if you can join. These are put in place to ensure your safety during the study and to make sure the results are clear.
It's important to discuss your full medical history with the study team to see if this study is right for you. They will explain all the requirements in detail.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with multiple myeloma?
- Has your multiple myeloma come back after treatment, or is it no longer responding to treatment?
- Are you able to attend regular appointments at the study clinic or hospital?
What does participation involve?
If you decide to take part in this study, you'll be given the new drug XMAB24306 along with daratumumab. Since this is an early-stage study, you would attend regular appointments at the hospital or clinic. These visits would involve check-ups, blood tests, and possibly other assessments like scans, to monitor your health and how you're responding to the treatment. The research team will also be checking for any side effects.
The specific number and frequency of visits, along with the duration of the treatment and follow-up, would be fully explained by the study team. Usually, there's a treatment period followed by a follow-up period where your health is still monitored. All treatments and assessments directly related to the study would be provided free of charge.
Potential risks and benefits
Locations (3)
- —UnverifiedNorway
- —UnverifiedDenmark
- —UnverifiedSpain
Common questions
What is multiple myeloma?
Multiple myeloma is a type of cancer that develops from plasma cells. These are a type of white blood cell made in the bone marrow.
What does 'relapsed/refractory' mean?
It means the multiple myeloma has either come back after treatment, or is not responding well to current treatments.
What is the new drug called?
The new drug being tested is called XMAB24306. It is being given with an existing drug called daratumumab.
Why is this study being done?
This study is being done to check if the new drug combination is safe and to understand how the body handles the new drug XMAB24306.
What 'phase' is this study?
This is an early-stage (Phase I) study, meaning it's one of the first times this new drug combination is being tested in people.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.